The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Managing hematological and GI toxicities in patients with lung cancer
Mariana Brandão, MD, PhD, Jules Bordet Institute, Brussels, Belgium, emphasizes the importance of using granulocyte-colony stimulating factor (g-CSF) to address hematological toxicity while also monitoring for iron deficiency. For gastrointestinal (GI) toxicity, careful review of baseline CT scans is needed to identify early signs of interstitial lung disease (ILD) or pneumonia, thereby minimizing the risk of complications during treatment. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
